特一藥業(002728.SZ)11天7板,旗下止咳和退燒藥產品受熱捧
格隆匯11月21日丨新冠藥概念股特一藥業(002728.SZ)今日再度漲停,報價30.42元,股價創2017年3月以來新高,該股近11個交易日內走出7個漲停板,且11月已累漲超120%,最新市值67.43億元。資料顯示,特一藥業主要從事中成藥品、化學制劑藥品、化學原料藥的研發、生產和銷售。近期持續獲市場關注,主要源於其在止咳和退燒藥方面的產品受熱捧。半年報數據顯示,公司呼吸類中成藥主要有止咳寶片、蒲地藍消炎片、感冒靈顆粒等,主要用於止咳和清熱。特一藥業在近日披露投資者關係活動記錄表公吿,其中提到,公司希望在銷售市場正常的情況下,用5-8年的時間,將公司核心產品特一牌止咳寶片的年銷售量增長到24億片。還提到,在治療新冠肺炎方面,根據相關省市公佈的新型冠狀病毒感染肺炎中醫藥防治方案來看,公司的中成藥蒲地藍消炎片具有治療的功效。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.